Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,804,812
  • Shares Outstanding, K 27,851
  • Annual Sales, $ 0 K
  • Annual Income, $ -303,270 K
  • EBIT $ -326 M
  • EBITDA $ -330 M
  • 60-Month Beta 2.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.19

Options Overview Details

View History
  • Implied Volatility 82.82% (+1.02%)
  • Historical Volatility 63.01%
  • IV Percentile 41%
  • IV Rank 18.43%
  • IV High 177.65% on 07/01/25
  • IV Low 61.39% on 02/19/26
  • Expected Move (DTE 6) 31.24 (9.88%)
  • Put/Call Vol Ratio 6.00
  • Today's Volume 56
  • Volume Avg (30-Day) 139
  • Put/Call OI Ratio 3.92
  • Today's Open Interest 10,319
  • Open Int (30-Day) 9,598
  • Expected Range 284.90 to 347.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-3.66
  • Number of Estimates 6
  • High Estimate $-3.00
  • Low Estimate $-5.23
  • Prior Year $-3.29
  • Growth Rate Est. (year over year) -11.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
271.95 +16.25%
on 03/30/26
338.31 -6.55%
on 04/01/26
+6.23 (+2.01%)
since 03/10/26
3-Month
266.93 +18.44%
on 01/12/26
356.00 -11.20%
on 02/24/26
+27.69 (+9.60%)
since 01/09/26
52-Week
28.12 +1,024.25%
on 04/11/25
356.00 -11.20%
on 02/24/26
+287.67 (+1,010.43%)
since 04/10/25

Most Recent Stories

More News
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed...

PRAX : 316.14 (-1.28%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,...

PRAX : 316.14 (-1.28%)
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous...

PRAX : 316.14 (-1.28%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,...

PRAX : 316.14 (-1.28%)
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the  U.S....

PRAX : 316.14 (-1.28%)
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 316.14 (-1.28%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 316.14 (-1.28%)
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 316.14 (-1.28%)
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational...

PRAX : 316.14 (-1.28%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 316.14 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis Precision Medicines Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 339.51
2nd Resistance Point 333.53
1st Resistance Point 324.84
Last Price 316.14
1st Support Level 310.17
2nd Support Level 304.19
3rd Support Level 295.50

See More

52-Week High 356.00
Last Price 316.14
Fibonacci 61.8% 230.75
Fibonacci 50% 192.06
Fibonacci 38.2% 153.37
52-Week Low 28.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.